AISA Pharma Completes Enrollment in Phase 2 RECONNOITER Trial
AISA Pharma, Inc. has announced a significant milestone in its research journey by completing enrollment in the Phase 2 RECONNOITER trial for AISA-021, a promising treatment for systemic sclerosis-related Raynaud's phenomenon. This clinical trial involved 63 participants divided into two parts, allowing researchers to study dose efficacy and safety, followed by a randomized crossover study to ensure comprehensive data collection.
The Significance of AISA-021
AISA-021, which is a fourth-generation calcium channel antagonist, targets systemic sclerosis (SSc) and its associated symptom, Raynaud's phenomenon. This condition can manifest as painful episodes of reduced blood flow in extremities, particularly affecting fingers and toes. It's crucial to note that up to 5% of the global population experiences Raynaud's, not solely as a symptom of SSc but also in relation to conditions such as lupus and rheumatoid arthritis. Recent data have brought to light the potential risks associated with Raynaud's, linking it to an increased incidence of cardiovascular and thromboembolic diseases.
Expert Insights and Future Directions
Andrew Sternlicht, MD, the CEO and Founder of AISA Pharma, expressed his enthusiasm for reaching this enrollment milestone. "The dedication of the Flinders Medical University team has been invaluable as we explore AISA-021 for patients urgently needing new treatment options," he stated. The company looks forward to unblinding the trial and conducting a detailed analysis in the near future.
Corporate Developments
In addition to trial news, AISA Pharma has made strides in its corporate strategy. Key professionals, including Dr. Norman Stockbridge from S & S Consulting, will guide AISA Pharma in its Phase 3 trial design and U.S. regulatory submissions. Such collaborations aim to expedite the approval process for this essential treatment.
Innovations in Manufacturing
AISA Pharma has pioneered an innovative synthetic process to produce cilnidipine with ultra-high purity, reflecting the company’s commitment to quality. This development not only enhances the drug's efficacy but also adds to its potential for pain relief, a benefit identified in preliminary NIH studies.
AISA-021: A Unique Approach to Treatment
The formulation of AISA-021 demonstrates distinct characteristics compared to its predecessors. Cilnidipine, the active ingredient, is recognized for its selective action on the N-type calcium channel, positioning it as a unique therapeutic option against hypertension. Its historical usage in certain Asian markets has paved the way for consideration in regions like the U.S. and Canada, where it remains unapproved, despite its promising outcomes in hypertension treatment.
The Impact of Systemic Sclerosis and Raynaud's Phenomenon
Systemic sclerosis represents one of the most severe autoimmune disorders, impacting around 100,000 individuals across America. Tragically, half of the patients diagnosed may succumb to the disease within a decade, emphasizing the need for more effective treatments. Among the myriad symptoms these patients face, Raynaud's phenomenon emerges as one of the most challenging, often described as severely debilitating. Unfortunately, the landscape of approved oral drugs specifically targeting Raynaud's remains starkly empty globally.
A Commitment to Patients
AISA Pharma, established in 2019, operates from Boston, MA, with a clear mission: to deliver innovative treatments to patients grappling with severe conditions. The company's focused approach and clinical efforts signify a promising upward trajectory in the biopharmaceutical domain.
Frequently Asked Questions
What is AISA-021 and its purpose?
AISA-021 is a fourth-generation calcium channel antagonist developed to treat systemic sclerosis-related Raynaud's phenomenon.
How many participants were involved in the RECONNOITER trial?
The RECONNOITER trial involved 63 participants, contributing to its comprehensive evaluation process.
Who is consulting for AISA Pharma on the trial?
Dr. Norman Stockbridge, a former FDA Division Director, is consulting for AISA Pharma on regulatory strategies and trial design.
Where is AISA Pharma located?
AISA Pharma is based in Boston, MA, and has been operational since 2019.
What are the key patient impacts of Raynaud's in systemic sclerosis?
Patients with systemic sclerosis often experience debilitating Raynaud's symptoms, which can significantly affect their quality of life by causing extreme pain and discomfort.
